Last update: Dec. 4, 2020
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
We do not have alternatives for Triptorelin.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Triptorelin is also known as
Triptorelin in other languages or writings:
Triptorelin belongs to this group or family:
Main tradenames from several countries containing Triptorelin in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | ≈ 0 | % |
Molecular weight | 1312 | daltons |
Protein Binding | ≈ 0 | % |
VD | 0,4 | l/Kg |
pKa | 9,5 | - |
Tmax | 0,6 ± 0,3 | hours |
T1/2 | 5,1 ( 2,5 - 13,8) | hours |
Write to us at elactancia.org@gmail.com
e-lactancia is a resource recommended by El Parto Es Nuestro from Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
A synthetic decapeptide, similar to gonadorelin, analogue of natural luteinizing hormone releasing hormone (LHRH). Indicated in in vitro fertilization treatments before stimulation with exogenous gonadotropins for ovarian stimulation. Subcutaneous administration daily for 10 to 25 days per menstrual cycle. It is also used in carcinomas of the prostate and breast, endometriosis, and uterine fibroids.
Since the last update, we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data (high molecular weight and high volume of distribution) make it unlikely that significant amounts will transfer into breastmilk.
Due to its protein nature, it is inactivated in the gastrointestinal tract (Van Leusden 1994, Fraser 1993), not being absorbed (practically zero oral bioavailability), which hinders its transfer into the infant's plasma from breastmilk, except in premature infants and the immediate neonatal period, when there may be greater intestinal permeability.
A similar LHRH analogue, buserelin is excreted in breastmilk in negligible or undetectable amounts and did not cause hormonal alterations in infants breastfed by mothers who were taking it (Dewart 1987), or alterations in lactation (Fraser 1989).
Increased prolactin has been observed in women treated with gonadorelin analogues and gonadotropins (Cavagna 2005, Kamel 1994, Meldrum 1992), although the findings are not consistent (Chantilis 1995).
See below the information of these related products: